Obesity Clinical Trial
Official title:
Impacts of Sugar-Sweetened Beverage Consumption on Body Weight Regulation
The obesity epidemic is a major public health problem. Weight gain is strongly associated with an increase in the incidence of complex health conditions such as type 2 diabetes (T2D), cardiovascular disease, stroke, and cancers. Behaviours linked to food and beverage consumption can greatly affect body weight. Frequent consumption of sugar-sweetened beverages such as carbonated soft-drinks, energy and sport drinks, fruit juices from concentrate, soda and flavoured milk and water is considered to be an unhealthy dietary behaviour. This project will investigate how variations in an individual's genes may impact their consumption of SSBs and thus body fatness. Specifically, the project will aim to investigate whether genetic variation in the taste receptors TAS1R2 and TAS1R3 can influence an individuals' perception and liking of a sweet palate and their intake of SSBs in UK. This study will be an experimental study that evaluates human body composition by different measurements. Additionally, two different biomarkers will be used for the study, such as blood and urine samples. Blood samples are the preferred source for DNA testing, rather than saliva. Urine samples will be used to look at the sugar level in the human body as a measure of body composition using deuterium dilution techniques. Around 128 adult volunteers will be recruited from Aberdeen, UK to participate in the study, which will take approximately one week to complete for each individual.
To achieve this study, recruited volunteers (n=128), aged 18 years and older will visit the Rowett Institute at the University of Aberdeen on one occasion, their body composition will be measured by 3 methods: BOD POD, Tanita scales, and deuterium dilution and their consumption of SSBs will be assessed using 24h dietary recall (once in the lab and once at home over the phone). In addition, a urine sample will be collected and assessed for potential markers of sugar. Individuals will have a blood sample (up to 5 ml) taken to determine genetic variation in their taste receptors and they will also undergo a taste test using randomised tasting of a panel of 9 different sugar solutions measured in triplicate (in total they will taste 27 little cups). The researcher will advise all the study subjects to come to a designated room in the Rowett Research Institute to complete the measurement regime at a pre-determined time between 6:30 am - 3:00 pm on their appointment day with about 2 participants per day. Each subjects measurments will take 4 hours to complete. Volunteers will complete informed consent before starting participate in the study: Pre visit: • Volunteers will be asked not to consume any food or drink other than water for 10 hours before their site visit, and avoid heavy exercise for 12 hours before to improve the accuracy of the body composition measurements. Phase I: - Volunteers will be asked to collect (fasted) urine sample to determine normal markers for sugar in their body. This will also be used to determine background isotope levels for the deuterium dilution protocol (5 minutes for collecting urine sample) - Measurement of weight and height (BMI) (5 minutes) - Deuterium dilution (consumption of deuterium dose; volume determined by the subjects body weight) (10 minutes). - Demographic questionnaire (10 minutes). - 24-h recall of SSB intake (face to face) (10 minutes). Rest Period Phase II: - Tanita scale (5 minutes). - BOD POD (10 minutes). Rest Period Phase III: - Blood sample (15 minutes). - Taste test (sugar solution) (50 minutes). - Final urine sample (5 minutes). Follow Up: • 24-h recall SSB intake after 1 week (10 minutes). The compulsory tests are: urine sample, measuring body composition by (deuterium, Tanita and Bod Pod), and demographic questionnaire, 24-h recall of SSB intake (face to face and phone interview), measuring weight and height (BMI) and Blood sample for genetics and the taste test. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |